|
Real-time
Boerse Muenchen
12:43:58 2026-09-08 EDT
|
5-day change | 1st Jan Change | ||
| 178.80 EUR | +0.51% |
|
+3.85% | +38.28% |
Company Valuation: Axsome Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,424 | 3,349 | 3,766 | 4,100 | 9,207 | 10,826 | - | - |
| Change | - | 135.22% | 12.44% | 8.87% | 124.55% | 17.58% | - | - |
| Enterprise Value (EV) 1 | 1,387 | 3,243 | 3,558 | 3,966 | 9,072 | 10,670 | 10,391 | 9,927 |
| Change | - | 133.87% | 9.72% | 11.46% | 128.76% | 17.61% | -2.61% | -4.46% |
| P/E | -10.9x | -16.8x | -15.1x | -14.1x | -49.6x | -77.3x | 44.9x | 16.2x |
| PBR | 90.9x | 30.6x | 19.7x | 72.2x | 105x | 137x | 36.1x | 13.4x |
| PEG | - | -0.5x | -1x | -1x | 1.3x | 2.8x | -0x | 0x |
| Capitalization / Revenue | - | 66.9x | 13.9x | 10.6x | 14.4x | 11.2x | 6.93x | 4.83x |
| EV / Revenue | - | 64.8x | 13.1x | 10.3x | 14.2x | 11x | 6.65x | 4.43x |
| EV / EBITDA | -11.1x | -18.5x | -15.8x | -14.5x | -56.7x | -79.3x | 48.6x | 20.9x |
| EV / EBIT | -11.1x | -18x | -15.3x | -14.1x | -54.4x | -78.9x | 36.3x | 12.1x |
| EV / FCF | -12.8x | -27.7x | -24.4x | -30.8x | -96.6x | -68.1x | 26.6x | 13.6x |
| FCF Yield | -7.83% | -3.61% | -4.09% | -3.24% | -1.03% | -1.47% | 3.76% | 7.33% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -3.47 | -4.6 | -5.27 | -5.99 | -3.68 | -2.675 | 4.606 | 12.76 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | 50.04 | 270.6 | 385.7 | 638.5 | 966.2 | 1,562 | 2,239 |
| EBITDA 1 | -124.6 | -175.4 | -225 | -273.6 | -159.9 | -134.5 | 213.6 | 475.3 |
| EBIT 1 | -124.7 | -179.8 | -231.8 | -280.6 | -166.8 | -135.1 | 286.5 | 823.1 |
| Net income 1 | -130.4 | -187.1 | -239.2 | -287.2 | -183.2 | -140.3 | 255.3 | 721 |
| Net Debt 1 | -37.38 | -106.6 | -208.1 | -134.6 | -135.2 | -156.5 | -435.3 | -898.9 |
| Reference price 2 | 37.78 | 77.13 | 79.59 | 84.61 | 182.64 | 206.68 | 206.68 | 206.68 |
| Nbr of stocks (in thousands) | 37,692 | 43,426 | 47,320 | 48,462 | 50,413 | 52,381 | - | - |
| Announcement Date | 3/1/22 | 2/27/23 | 2/20/24 | 2/18/25 | 2/23/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 19.17x | 4.48x | 10.55x | 0.47% | 82.65B | |
| 20.49x | 4.36x | 13.56x | 2.4% | 59.87B | |
| -17.31x | 25.92x | -17.11x | -.--% | 58.11B | |
| 35.71x | 12.16x | 23.32x | -.--% | 50.35B | |
| 21x | 4.65x | 13.24x | 0.69% | 46.62B | |
| 38.13x | 3.6x | 13.71x | -.--% | 32.63B | |
| 56.56x | 3.61x | 27.99x | -.--% | 25.69B | |
| 67.46x | 7.16x | 43.58x | -.--% | 22.49B | |
| 23.59x | 5.06x | 13.17x | -.--% | 16.33B | |
| Average | 29.42x | 7.89x | 15.78x | 0.4% | 43.86B | |
| Weighted average by Cap. | 23.26x | 8.67x | 12.27x | 0.54% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AXSM Stock
- 19X Stock
- Valuation Axsome Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
